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ABSTRACT   Antiphospholipid antibody syndrome (APS) is an immune disease in which 
antiphospholipid antibodies cause hypercoagulability and thromboembolic complications. 
We experienced APS cases associated with systemic lupus erythematosus with three-vessel 
lesions of the coronary artery. After a below knee amputation on a 60-year-old woman with 
APS, she complained of chest pain at rest. An electrocardiogram showed an ST depression 
and a coronary angiography showed complicated three-vessel disease, as a result she was 
referred to the cardiac surgery department. A coronary artery bypass with arterial grafts was 
performed along with postoperative anticoagulant and antiplatelet therapy, and the short-term 
graft patency was good. Case reports of coronary artery bypass grafts for secondary APS are 
rare, so we report here on our case and our strategy to treat thromboembolic complications.
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〈Case Report〉
BACKGROUND
   Antiphospholipid antibody syndrome (APS) 
is an immune disease in which antiphospholipid 
an t i bod i e s  c ause  hype rcoagu l ab i l i t y  and 
thromboembolic complications. Patients with 
APS  su ffe r  sys t emic  d i so rde r s  i nc lud ing 
cardiovascular disease１－４）. There are some reports 
on cardiovascular surgery for APS patients which 
showed higher operation risks due to perioperative 
thromboembolic complications５－８）. There are 
two types of APS, idiopathic and secondary. Most 
published reports have been about cardiac surgery 
for idiopathic APS, with only a few case reports on 
secondary APS１，５－８）.
   We experienced a case of on-pump beating-
heart coronary artery bypass grafting (CABG) 
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for a patient with secondary APS associated with 
systemic lupus erythematosus (SLE). Case reports 
on CABG for secondary APS are rare, so we 
report here on our case and our strategy to treat 
thromboembolic complications.
CASE REPORT
   A 60-year-old female presented with chest 
pain at rest. She had a long history of medical 
problems prior to this complaint. In her 30s, she 
was diagnosed with proteinuria. Later, after two 
miscarriages, she was diagnosed with both SLE 
and APS. She had a history of taking high doses 
of prednisolone to treat her SLE. When she was 
referred to our department, her SLE was kept under 
control with 3 mg of prednisolone. Although she 
had undergone repeated intravascular interventions 
for arteriosclerosis obliterans (ASO), at the age of 
57, her stenotic lesions became much worse. She 
eventually had a below knee amputation and she 
complicated of chest pain at rest on the sixth day 
after the operation. After an electrocardiogram 
(ECG) showed an ST depression, an echocardiogram 
revealed anterior and lateral wall motion asynergy, 
and a coronary angiography showed complicated 
three-vessel disease, she was referred to our cardiac 
surgery department. 
   She had an internal shunt in her left forearm for 
analgesics and even narcotics due to the severe pain 
in her extremities after her amputation. A blood 
test showed anemia due to renal failure. Additional 
tests showed hemoglobin: 6.6 g/dL, creatinine: 6.69 
mg/dL, urea nitrogen: 37 mg/dL, brain natriuretic 
peptide: 1893.3 pg/mL, lupus anticoagulant: 1.49 
(standard value [SD]: < 1.3), anticardiolipin IgG 
antibody (Ab): 19 U/mL, anti-ss DNA IgG Ab: < 10 
AU/mL, anti-ds DNA IgG Ab: < 10 IU/mL, C3: 110 
mg/dL (SD: 86-160), C4: 30 mg/dL (SD: 17-45).
   In another detailed examination of the condition 
of the heart, an ECG showed an ST depression 
in leads V4-V6. Transthoracic echocardiography 
showed anterior and lateral wall motion asynergy 
associated with left ventricular diameters of 61 mm 
(diastolic) and 48 mm (systolic), a left ventricular 
ejection fraction of 52%, an E/A ratio of 0.7, an e/
e’ ratio of 15.1 and a deceleration time of 62 ms. 
There was no specific valvular disease. A coronary 
angiography showed stenotic lesions. Fig. 1 shows 
stenitic segment 1 (90%) and segment 4 (99%). 
Fig. 2 shows totally occluded segment 11 and good 
Figure.1  
Figure. 2
Fig. 1. Coronary angiography (CAG) showing the 
right coronary artery (RCA). The RCA was severely 
stenosed at the proximal (yellow arrows) and posterior 
descending branches(red arrows).
Fig. 2. CAG showing the LCx which was occluded 
proximally and had collateral flow from the LAD. Red 
arrows shows high lateral branch, and yellow arrows shows 
posterior lateral branch. Those are perfused by collateral 
flow from LAD.
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collateral flow from the left anterior descending 
artery (LAD). Fig. 3 shows stenotic  segment 5 
(50%), segments 6-7 (diffusely 90%), segment 8 
(90%) and segment 9 (90%).
   We planned an all arterial graft bypass in case of 
acute venous graft occlusion due to the APS. We 
harvested the internal thoracic arteries and right 
gastroepiploic artery (RGEA). The RGEA had a 
stenotic section shaped like a coil, but an ultrasonic 
flow meter showed that distal perfusion was not 
restricted. A cardiopulmonary bypass (CPB) was 
established with blood supply to the ascending aorta 
and bicaval venous drainage. The anastomoses 
were performed under beating-heart conditions. We 
anastomosed the right intrathoracic artery (RITA) 
to the LAD, followed by the diagonal branch. The 
left intrathoracic artery (LITA) was anastomosed to 
the obtuse marginal (OM) branch. The RGEA was 
anastomosed to the posterior descending branch 
(PD) and the posterolateral branch (PL). Graft flows 
were measured with an ultrasonic flow meter and 
were deemed acceptable. The graft flow for RITA-
LAD-D was 20 ml/min with a pulsatility index (PI) 
of 2.8, the LITA-OM flow was 16 ml/min with PI 
3.0 and the GEA-PD-PL flow was 31 ml/min with 
PI 2.5. After the anastomoses, circulation was easily 
weaned off the CPB. A half dose of protamine was 
administered, but it took some time to achieve 
hemostasis because the activated clotting time 
(ACT) was > 150 seconds. Fig.4 and Fig.5 showed 
postoperative CT angiography.
   Three hours after the operation, a heparin infusion 




Fig. 3. CAG showing the proximal LAD was diffusely 
stenosed (yellow arrows) and the diagonal branch was 
also severely stenosed (red arrow).
Fig. 4. Postoperative CT angiography showing the RGEA 
graft. The RGEA graft had a coil-like stenosed section 
(yellow arrow). The RGEA was not occluded, but there 
was less blood flow past the stenotic area.
Fig. 5. Postoperative CT angiography 
showing the patent bilateral ITA grafts.
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a nasogastric tube. Although her hemodynamics 
was stable, there was bleeding. Thus, we used 
a blood transfusion for her anemia. Nafamostat 
was used in addition to the heparin, because a 
previous report have shown that some patients 
with APS had complications with heparin induced 
thrombocytopenia (HIT)６）. An oral antiplatelet 
was begun on postoperative day (POD) 1, and 
hemodiafiltration was started on POD 2. We 
maintained her sinus rhythm with a β-blocker and 
antiarrhythmic drugs. Her bleeding ceased on POD 
3. From POD 4, she took two oral antiplatelets and 
two anticoagulants, warfarin and nafamostat. After 
the prothrombin time / international normalized ratio 
(PT-INR) was prolonged enough, we prescribed just 
two antiplatelets and warfarin. Though it took time 
to cure an infection in her superficial wound, she 
had no perioperative thromboembolic complications. 
After her wound healed, she was transferred to 
another hospital to continue her rehabilitation for 
her artificial leg.
   Microscopic examination showed that the 
excised internal thoracic artery had myxomatous 
degeneration in the tunica intima and tunica 
media, and that the gastroepiploic artery had some 
myxomatous degeneration.
DISCUSSION
   In the general population, just 1-5% of people 
test positive for antiphospholipid antibodies. Only 
a few of that small group will eventually develop 
antiphospholipid syndrome１，２）. There are thought 
to be 40-50 APS patients per 100,000 people. 
There are several ways APS can express: carriers 
who have the antibody without any symptoms, 
“classic” APS with refractory thrombosis, APS 
causing refractory miscarriage and catastrophic 
APS with acute systemic organ dysfunction due 
to micro-embolisms１－４）.Classification criteria for 
antophospholipid antibody syndrome was addressed 
at a preconference workshop, preceding the 
Eleventh International Congress on antiphospholipid 
antibodies. The classification includes clinical and 
laboratory section. Clinical criteria includes vascular 
thrombosis and pregnancy morbidity, laboratory 
criteria includes positivity of Lupus anticoagulant, 
anticardiolipin antibody and anti-β2 glycoprotein 
antibody５）. In our case, the patient had refractory 
arteriosclerosis obliterans and was on hemodialysis 
due to lupus nephritis. She also had a medical 
history of refractory miscarriages and stroke, but 
there was no history of thromboembolisms except 
for superficial veins. She had taken warfarin to 
prevent thromboembolisms and three antiplatelets 
for repeated ASO restenosis.
   There are two types of APS, primary and 
secondary. Primary APS does not have any 
associated diseases, and secondary APS has 
associated immune diseases like SLE and systemic 
sclerosis. In this case, we believe that our patient 
has secondary APS which is associated with her 
SLE１）.
   Hedge et al. reported on a series of nine APS 
patients who underwent cardiac surgery. Three cases 
had thromboembolic complications, two had HIT 
and one had graft occlusions which necessitated a 
reoperation８）. Though the perioperative risk was 
high, our case here had a good postoperative course 
without any major APS-specific adverse events 
other than a superficial incision infection. Most 
patients with APS are older and so they are usually 
given vein grafts for their CABG. In this case, we 
only used arterial grafts to prevent graft occlusion８）. 
Her ITAs and RGEA had no specific findings of 
arteritis pathologically, however her RGEA had a 
coil-like stenosed section. There are currently no 
published reports on long-term arterial graft patency 
for APS patients, therefore long-term follow-up of 
this patient will be important.
   Several kinds of anticoagulants and antiplatelets 
were used due to previous reports on  postoperative 
thromboembolic complications. Some APS patients 
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in those reports had a longer preoperative ACT and 
activated partial thrombin time (APTT) than usual. 
Matsuyama et al. reported on an APS patient with 
an elongated ACT which was controlled with a 
higher ACT target and who went on to avoid any 
thromboembolic complications６）. In our case, both 
the preoperative ACT and APTT were in the normal 
range, so we used our institution’s usual ACT 
standard of < 400 seconds. HIT was also reported 
as a postoperative complication of APS, therefore 
nafamostat was used along with heparin during and 
after the operation. The operation was successfully 
concluded without any thrombus occurring in the 
cardiopulmonary circuit.
   After circulation was weaned off the CPB, we 
could not achieve hemostasis without protamine 
administration. A half dose of protamine brought 
the patient into hemostasis and ACT was considered 
controlled at < 150 sec. There was no bleeding from 
the anastomoses, but there was considerable amount 
of bleeding from connective tissues and from the 
bone marrow of the sternum. A transfusion of red 
blood cells was necessitated perioperatively, but we 
did not transfuse fresh frozen plasma or platelets 
and the bleeding ceased on POD 3. We believe that 
if there was no major bleeding necessitating surgical 
repair, bleeding would cease even while taking 
several kinds of antiplatelets and anticoagulants 
due to the postoperative hypercoagulative phase. 
We also believe that  APS patients have an 
increased risk of acute graft thrombosis without 
enough antiplatelets and anticoagulants during the 
postoperative hypercoagulative phase.
   Though there was more hemorrhaging than usual 
due to the combination use of antiplatelets and 
anticoagulants, the patient had no thromboembolic 
complications. We believe that post cardiac surgery 
care for APS patient should be focused on coping 
with potential thromboembolic complications.
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